News

Under the deal, Celgene will pay $232 per share in cash for Receptos, which is focused on developing therapeutic candidates for the treatment of immune and metabolic diseases.

The company markets Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and also develops treatments for multiple sclerosis (MS), HIV, adrenomyeloneuropathy (AMN) and pain. The

This new CPMA drug delivery platform technology, developed by Rexahn, enables more precise, targeted delivery of anti-cancer drugs directly into cancer cells. "There is a significant unmet need

Treatment with Radiesse (+) immediately replenishes lost volume as well as providing significant reduction in pain due to the addition of lidocaine. "With the introduction of Radiesse (+),

The company develops a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue

The company noted that this orphan designation is valid for all applications of DPX-Survivac in ovarian cancer without restriction to a specific stage of disease. DPX-Survivac activates and

APG101 is a fully-human fusion protein that inhibits the CD95 ligand, a member of the tumor necrosis factor (TNF) family. It isindicated to treat glioblastoma multiforme in China,

As part of the deal, Laboratorios Saval will be responsible to secure regulatory and pricing approval as well as provide marketing and distribution of the product in Bolivia,

As part of the deal, both the parties will carry out studies designed to improve the mechanistic understanding of fibrosis, explore patient segmentation based on disease characteristics and/or